(c) 2024 PillSync.com

24 HR Oxybutynin chloride 15 MG Extended Release Oral Tablet

1 INDICATIONS AND USAGE Oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ( 1 ) Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Zydus Pharmaceuticals (USA) Inc.


4 years ago ROUND WHITE 257 24 HR Oxybutynin chloride 15 MG Extended Release Oral Tablet

ROUND WHITE 257

16 HOW SUPPLIED/STORAGE AND HANDLING

OXYBUTYNIN Chloride Extended-release Tablets USP, 5 mg are white to off-white, round, beveled-edged, biconvex, coated-tablets debossed on one side with "255" and plain on other side and are supplied as follows: NDC 68382-255-06 in bottle of 30 tablets with child-resistant closure NDC 68382-255-14 in bottle of 60 tablets with child-resistant closure NDC 68382-255-16 in bottle of 90 tablets with child-resistant closure NDC 68382-255-01 in bottle of 100 tablets NDC 68382-255-05 in bottle of 500 tablets NDC 68382-255-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets

OXYBUTYNIN Chloride Extended-release Tablets USP, 10 mg are white to off-white, round, beveled-edged, biconvex, coated-tablets debossed on one side with "256" and plain on other side and are supplied as follows: NDC 68382-256-06 in bottle of 30 tablets with child-resistant closure NDC 68382-256-14 in bottle of 60 tablets with child-resistant closure NDC 68382-256-16 in bottle of 90 tablets with child-resistant closure NDC 68382-256-01 in bottle of 100 tablets NDC 68382-256-05 in bottle of 500 tablets NDC 68382-256-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets

OXYBUTYNIN Chloride Extended-release Tablets USP, 15 mg are white to off-white, round, beveled-edged, biconvex, coated-tablets debossed on one side with "257" and plain on other side and are supplied as follows: NDC 68382-257-06 in bottle of 30 tablets with child-resistant closure NDC 68382-257-14 in bottle of 60 tablets with child-resistant closure NDC 68382-257-16 in bottle of 90 tablets with child-resistant closure NDC 68382-257-01 in bottle of 100 tablets NDC 68382-257-05 in bottle of 500 tablets NDC 68382-257-77 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Storage Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Protect from moisture and humidity. Keep out of reach of children.


More pills like ROUND 257

Related Pills

oxybutynin tablet film coated extended release

zydus pharmaceuticals (usa) inc.

carvedilol 25 MG Oral Tablet

Solco Healthcare US LLC

alprazolam tablet

contract pharmacy services-pa

alprazolam tablet

contract pharmacy services-pa

Alprazolam 0.5 MG Oral Tablet

Contract Pharmacy Services-PA












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site